Pfizer Says 2nd Circ. Can't Review Lipitor FCA Suit

Law360, New York (February 10, 2014, 4:26 PM EST) -- Pfizer Inc. told the Second Circuit on Monday it lacks jurisdiction to review a False Claims Act dispute over alleged off-label marketing of the company's cholesterol drug Lipitor, arguing that a lower court failed to resolve all of the claims in the whistleblower suit.

Pfizer said a New York federal judge had properly dismissed claims by Jesse Polansky that the pharmaceutical giant marketed Lipitor for unapproved uses, but also "inadvertently" dismissed his claim that he was fired after raising concerns about the conduct. The employment claim...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.